Potential application of sofosbuvir-based treatment for chronic hepatitis C in China
10.3760/cma.j.issn.1007-3418.2018.03.012
- VernacularTitle:基于索磷布韦的丙型肝炎治疗方案在中国的价值和应用潜力
- Author:
Qiongfang ZHANG
1
;
Dazhi ZHANG
Author Information
1. 400010,重庆医科大学附属第二医院感染病科
- Keywords:
Hepatitis C,chronic;
Therapy;
Sofosbuvir;
Direct-acting antiviral agents
- From:
Chinese Journal of Hepatology
2018;26(3):233-237
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis C (CHC) has a prevalence rate of 0.43％ in China and approximately 10 million chronically infected people are in urgent need of treatment.Since the beginning of 2013,pan-genotypic sofosbuvir (SOF) with its potent antiviral activity,minimal drug resistance,less drug-drug interactions and good safety has created a new era in HCV treatment.Its combination with ribavirin,in single tablet regimen with either ledipasvir or velpatasvir has been widely used in about 1.6 million patients worldwide.Furthermore,SOF-based therapy is proven to be effective and safe in serious or terminal illness such as decompensated cirrhosis,liver or kidney transplantation,HIV or HBV co-infections,bleeding disorders,intravenous drug users,adolescents,and elderly.Therefore,SOF-based regimens would fill the unmet medical needs of our patients with HCV.
